Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients

Ho, Shin-Shin; Tsai, Tsen‐Fang

doi:10.1007/s40291-022-00603-4

Cited by 5 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MICA *010- HLA-B *4601- Cw *01 haplotype displayed a greater incidence of Type I and II psoriasis. Significantly, MICA *010 exhibited a robust correlation with HLA-Cw *01 [ 28 ], which correspond to two prominent risk loci in the Asian population, including Taiwanese subjects [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Functional MICA Variants Are Differentially Associated with Immune-Mediated Inflammatory Diseases

Wang,

Tan,

et al. 2024

IJMS

View full text Add to dashboard Cite

As the principal ligand for NKG2D, MICA elicits the recruitment of subsets of T cells and NK cells in innate immunity. MICA gene variants greatly impact the functionality and expression of MICA in humans. The current study evaluated whether MICA polymorphisms distinctively influence the pathogenesis of psoriasis (PSO), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) in Taiwanese subjects. The distributions of MICA alleles and levels of serum soluble NKG2D were compared between healthy controls and patients with PSO, RA, and SLE, respectively. The binding capacities and cell surface densities of MICA alleles were assessed by utilizing stable cell lines expressing four prominent Taiwanese MICA alleles. Our data revealed that MICA*010 was significantly associated with risks for PSO and RA (PFDR = 1.93 × 10−15 and 0.00112, respectively), while MICA*045 was significantly associated with predisposition to SLE (PFDR = 0.0002). On the other hand, MICA*002 was associated with protection against RA development (PFDR = 4.16 × 10−6), while MICA*009 was associated with a low risk for PSO (PFDR = 0.0058). MICA*002 exhibited the highest binding affinity for NKG2D compared to the other MICA alleles. Serum concentrations of soluble MICA were significantly elevated in SLE patients compared to healthy controls (p = 0.01). The lack of cell surface expression of the MICA*010 was caused by its entrapment in the endoplasmic reticulum. As a prevalent risk factor for PSO and RA, MICA*010 is deficient in cell surface expression and is unable to interact with NKG2D. Our study suggests that MICA alleles distinctively contribute to the pathogenesis of PSO, RA, and SLE in Taiwanese people.

show abstract

Section: Discussionmentioning

confidence: 99%

Functional MICA Variants Are Differentially Associated with Immune-Mediated Inflammatory Diseases

Wang,

Tan,

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Clinically, it is most commonly associated with erythroderma, pustular psoriasis, and psoriatic arthritis [24,25]. Family history is often positive and HLA-Cw1 patients respond less well to biologic therapy and show resistance to alefacept [31,32]. HLA-Cw1 also uses KIR receptors as ligands, in particular, KIR2DL2 and KIR2DL3 [33,34].…”

Section: The Significance Of Antigen Presentation and Human Leukocyte...mentioning

confidence: 99%

“…Droplet psoriasis Type I psoriasis [27] In the general population varies from 14.1% to 59.1% [27]; more frequently in Caucasian patients than in the Asian population [27,39] Responds better to treatment with methotrexate, biologic drugs directed against (IL)-12/23, IL-17, and IL-23 [12] HLA Cw1 Erythroderma, pustular psoriasis, and psoriatic arthritis [12] Most common in the Asian population [12] Worse response to biologic therapy resistance to alefacept [31,32]…”

Section: Hla Cw6mentioning

confidence: 99%

The Role of Epigenetic Factors in the Pathogenesis of Psoriasis

Olejnik-Wojciechowska,

Boboryko,

Bratborska

et al. 2024

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease, the prevalence of which is increasing. Genetic, genomic, and epigenetic changes play a significant role in the pathogenesis of psoriasis. This review summarizes the impact of epigenetics on the development of psoriasis and highlights challenges for the future. The development of epigenetics provides a basis for the search for genetic markers associated with the major histocompatibility complex. Genome-wide association studies have made it possible to link psoriasis to genes and therefore to epigenetics. The acquired knowledge may in the future serve as a solid foundation for developing newer, increasingly effective methods of treating psoriasis. In this narrative review, we discuss the role of epigenetic factors in the pathogenesis of psoriasis.

show abstract

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

Kim,

Jo,

Youn

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years. Methods The proportions of guselkumab-treated Asian patients (VOYAGE 1 and 2) achieving Psoriasis Area and Severity Index (PASI) 90 and PASI 100, Investigator’s Global Assessment (IGA) scores of 0/1 and 0, and Dermatology Life Quality Index (DLQI) scores of 0/1 (week 100 through week 252) were assessed. Non-responders were patients who met the treatment failure rules. Efficacy endpoints were analyzed using the as-observed methodology (no missing data imputation) for both studies and using non-responder imputation (for patients with any missing data) in VOYAGE 1. Safety outcomes were based on pooled data through week 252. Results Response rates through week 252 for 199 Asian patients in the guselkumab group in VOYAGE 1 and VOYAGE 2, respectively, were 76.8% and 80.6% (PASI 90), 26.8% and 38.7% (PASI 100), 64.3% and 87.1% (IGA 0/1), and 26.8% and 45.2% (IGA 0). DLQI (0/1) at week 252 was achieved by 52.7% of patients in VOYAGE 1 and 61.3% in VOYAGE 2, while DLQI (0) at week 252 was achieved by 32.7% of patients in VOYAGE 1 and 40.3% in VOYAGE 2. The safety profile was similar to the global population and remained consistent through 5 years. Asian patients were followed for a total of 814 patient-years (PY). Over 85% of the guselkumab-treated patients continued treatment through week 264. The rate of serious adverse events (AEs) at week 252 was 3.07/100 PY. Rates of AEs of interest were low: serious infections, 0.74/100 PY; nonmelanoma skin cancer (NMSC), no patients; malignancies other than NMSC, 0.12/100 PY; and no major adverse cardiovascular events (MACE). Conclusion These analyses confirm a continuous response over 5 years, indicating that guselkumab shows therapeutic longevity in Asian patients requiring long-term treatment for moderate-to-severe psoriasis. Trial Registration ClinicalTrials.gov identifiers: VOYAGE 1 [NCT02207231] and VOYAGE 2 [NCT02207244].

show abstract

Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients

Cited by 5 publications

References 49 publications

Functional MICA Variants Are Differentially Associated with Immune-Mediated Inflammatory Diseases

Functional MICA Variants Are Differentially Associated with Immune-Mediated Inflammatory Diseases

The Role of Epigenetic Factors in the Pathogenesis of Psoriasis

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

Contact Info

Product

Resources

About